Business
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
– Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed
About this update from Coherus Oncology, Inc.
[{"type":"text","content":"– Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses – – Data support continued evaluation of casdozokitug in combination with anti-PD-1 antibody treatments including ongoing Phase 2 cohort of casdozokitug with toripalimab in treatment refractory NSCLC – REDWOOD CITY, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from the ongoing Phase 1b/2 clinical trial of casdozokitug (casdozo), a first-in-class IL-27-targeting antibody, being presented at the 2023 ESMO Immuno-Oncology Congress taking place December 6 – 8, 2023 at Palexpo Exhibition Centre in Geneva, Switzerland. The presentation includes updated data for casdozo monotherapy dose escalation and expansion cohorts and a cohort evaluating treatment with casdozo in combination with the anti-PD-1 antibody pembrolizumab (pembro) in patients with non-small cell lung cancer (NSCLC) who have progressed after 2-4 prior lines of therapy, including chemotherapy and anti-PD-1 agents. Interleukin (IL)-27 is an immunoregulatory cytokine involved in suppressing anti-tumor immune responses and an important new target for cancer treatment. Casdozo is a first-in-class antibody, and the only clinical stage immunomodulatory cytokine antagonist targeting IL-27. “‘Cold’ and ‘excluded’ tumor immune microenvironments are the least likely to respond to checkpoint blockade and present a unique challenge to the field of cancer immunotherapy, and IL-27 production by tumor infiltrating macrophages may be one key mechanism by which tumors exclude key anti-tumor lymphocytes,” said Thomas Marron, M.D., Ph.D., Director, Early Phase Trials Unit, The Tisch Cancer Center. “The responses in pre-treated patients who have progressed on PD-1 blockade are extremely encouraging and warrant further investigation both in the relapsed/refractory setting and potentially up-front. The responses we saw in patients with squamous cell carcinoma are particularly intriguing, and further analysis of the tissue and blood of these patients will hopefully reveal biomarkers to further enrich for patients likely to respond to casdozo.” “We are pleased to see that casdozo has demonstrated immune activation and monotherapy anti-tumor activity with an ...